Track record

Successful track record of product development

LondonPharma demonstrated its expertise in repurposing through the sublingual delivery of a treatment for severe malaria in children.

The company developed a novel, sublingual formulation of artemether for the treatment of falciparum malaria, (severe malaria) in children using a sublingual spray device.

A separate joint venture company has since been formed with a partner to commercialise the use of the drug in this indication.

This underpins our strategy to take our product development programmes through to proof-of-efficacy in man and then license those programmes to corporate partners.

Print this page